LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lyell Immunopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.80+0.68 (+8.37%)
Close on Oct 19, 2026
- Market cap
- $205.60M
- P/E (TTM)
- –
- Dividend yield
- –
Lyell Immunopharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -949981.5%
- Net margin
- -920285.2%
- Return on equity, FY2025
- -87.0%
Financial strength
- Current ratio
- 5.36
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 183.1%
Valuation
- P/E ratio
- –
- Price to sales
- 7614.93
- Price to book
- 0.88
- Dividend yield
- –